Genetic Technologies Limited
GENE
$0.765
-$0.015-1.92%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -19.33% | -21.32% | -5.56% | -8.75% | -10.71% |
| Total Other Revenue | 28.81% | 25.60% | 9.97% | 6.28% | -23.20% |
| Total Revenue | -11.83% | -14.00% | -2.99% | -6.26% | -12.91% |
| Cost of Revenue | -9.62% | -11.86% | -18.96% | -21.69% | 8.48% |
| Gross Profit | -13.33% | -15.47% | 9.12% | 5.45% | -23.31% |
| SG&A Expenses | 10.98% | 8.24% | 3.44% | -0.05% | -14.00% |
| Depreciation & Amortization | -27.57% | -29.39% | -15.75% | -18.60% | 8.84% |
| Other Operating Expenses | -10.99% | -13.18% | 0.92% | -2.46% | 47.87% |
| Total Operating Expenses | -2.91% | -5.31% | -4.09% | -7.32% | 3.20% |
| Operating Income | -6.61% | -3.98% | 5.10% | 8.30% | -28.62% |
| Income Before Tax | 12.35% | 14.52% | -13.42% | -9.59% | -79.46% |
| Income Tax Expenses | -- | -- | -- | -- | 70.43% |
| Earnings from Continuing Operations | 12.21% | 14.38% | -16.50% | -12.56% | -80.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.21% | 14.38% | -16.50% | -12.56% | -80.94% |
| EBIT | -6.61% | -3.98% | 5.10% | 8.30% | -28.62% |
| EBITDA | -2.65% | -0.11% | 4.40% | 7.63% | -29.53% |
| EPS Basic | 34.74% | 36.41% | 6.70% | 9.90% | -50.79% |
| Normalized Basic EPS | 14.44% | 16.30% | 24.37% | 26.83% | -13.92% |
| EPS Diluted | 34.74% | 36.41% | 6.70% | 9.90% | -50.79% |
| Normalized Diluted EPS | 14.44% | 16.30% | 24.37% | 26.83% | -13.92% |
| Average Basic Shares Outstanding | 34.95% | 34.95% | 24.99% | 24.99% | 19.59% |
| Average Diluted Shares Outstanding | 34.95% | 34.95% | 24.99% | 24.99% | 19.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
